Research

AI and Pharma Deal Tracker, 2026

A dated list of 20 deals between AI companies and drugmakers in 2026, from Lilly and Nvidia in January to AstraZeneca and insitro in October, with the upfront payment separated from the milestone total for each.

By Ramanath, CTO & Co-Founder at Presenc AI · Last updated: November 2026

This page lists 20 deals announced between January 4 and October 16, 2026 in which a drugmaker partnered with an AI company. Only three of the 20 disclosed a clean upfront payment: $115 million from Lilly to Insilico Medicine, $40 million from AstraZeneca to insitro, and $30 million from Zealand Pharma to Generate Biomedicines. Seven disclosed no financial terms at all, including every deal with OpenAI and Anthropic. The list is as of November 13, 2026 and is not exhaustive.

Drug Discovery and Licensing Deals

"Near-term" means the company reported one figure that mixes the upfront payment with early milestones or fees. "Total" is the headline value if every milestone is met. Royalties are extra in most of these deals.

Date, 2026DrugmakerAI companyUpfront or near-termMilestones or totalScopeSource
Jan 4ServierInsilico MedicineUp to $32M in upfront and near-term R&D paymentsTotal up to $888MOncology discoveryBioSpectrum Asia
Early JanEli LillyNimbus Therapeutics$55M in upfront and near-term milestonesTotal up to about $1.3BOral obesity drug, computational chemistryNimbus release
Jan 8GSKNoetik$50M in upfront and near-term milestonesAnnual licence fees, amount not disclosedFive-year non-exclusive licence to cancer foundation modelsBusiness Wire
Jan 8PfizerBoltzNot disclosedNot disclosedExclusive models for structure prediction, affinity and biologics designBoltz release
JanuaryServierIktosNot broken outTotal above €1B, including upfront, research funding and milestonesSmall molecules in oncology and neurologypharmaphorum
JanuaryEli LillyChai DiscoveryNot disclosedNot disclosedBiologics design, plus a model built only for LillyGEN
Jan 20Johnson & JohnsonIsomorphic LabsNot disclosedNot disclosedMulti-target research across several drug typesIsomorphic Labs
Feb 9TakedaIambic TherapeuticsNot disclosedMilestone-based payments above $1.7BSmall molecules in cancer, gastrointestinal and inflammatory diseasepharmaphorum
Mar 29Eli LillyInsilico Medicine$115M upfrontTotal about $2.75BLicence to preclinical oral drugs, plus joint programmesInsilico release
Jun 22SK BiopharmaceuticalsInsilico MedicineUp to $18M in upfront and near-term milestonesTotal above $2.5BNeuroimmune disorders of the central nervous systemInsilico release
Jul 2TakedaInsilico MedicineAbout $60M in initiation fees, near-term payments and milestonesTotal about $600MDiscovery across Takeda's therapeutic areasInsilico release
Jul 30GSKRelation TherapeuticsNot broken outUp to $110M in upfront and milestones combinedHuman cell datasets for immunology, fibrosis and osteoarthritisBioXconomy
Sep 21AbbVieIambic TherapeuticsNot disclosedNot disclosedSmall molecules in immunology, neuroscience and oncologyAbbVie
Oct 13Zealand PharmaGenerate Biomedicines$30M upfront, plus up to $35M in early preclinical milestonesTotal milestones of nearly $1.2BTwo protein drug programmes for obesity and metabolic diseaseGenerate release
Oct 15 to 16AstraZenecainsitro$40M upfrontUp to about $1.46B in milestonesMASH and cardiomyopathiesBioXconomy

Compute, Platform and Enterprise Deals

These are not licensing deals. No molecule changes hands and there are no milestones. The two dollar figures are spending commitments.

Date, 2026DrugmakerAI companyDisclosed valueScopeSource
Jan 12Eli LillyNvidiaUp to $1B over five years, invested jointlyCo-innovation lab in the San Francisco Bay AreaNvidia
Apr 14Novo NordiskOpenAINot disclosedAI across discovery, manufacturing, supply chain and commercial workNovo Nordisk release
Apr 22MerckGoogle CloudUp to $1B, multi-yearGemini Enterprise across R&D, manufacturing, commercial and corporate functionsConstellation Research
May 20Bristol Myers SquibbAnthropicNot disclosedClaude for more than 30,000 employeesFierce Biotech
Sep 16Novo NordiskAnthropicNot disclosedClaude models and Claude Science in R&DEuronews

What the List Shows

  • The cash paid at signing is a small share of the headline. By our arithmetic, Lilly's $115 million is about 4% of the $2.75 billion Insilico total. AstraZeneca's $40 million is under 3% of the roughly $1.5 billion insitro could receive. See biobucks for how to read these figures.
  • Insilico signed four of the 20. Its four 2026 deals carry headline totals that add up to about $6.7 billion, against about $225 million in upfront and near-term payments, by our arithmetic on the company's own figures.
  • The frontier labs disclose no money. OpenAI's and Anthropic's pharma deals are software and model access agreements with no published value. Details are on the OpenAI and Novo Nordisk and Anthropic partnerships pages.
  • Lilly appears four times. Nimbus, Chai Discovery, Nvidia and Insilico. The Nvidia deal is covered on the Nvidia and Lilly lab page.

Conflicts and Gaps

  • SK Biopharmaceuticals and Insilico: the release headline says "up to" $2.5 billion and its body says the value "exceeds" $2.5 billion. pharmaphorum described the $18 million as an upfront payment, while the release calls it upfront and near-term milestones combined.
  • Merck and Google Cloud: Constellation Research dated the announcement April 22, 2026 and IT Brief dated it April 24. Coverage also differs on the length of the commitment.
  • AstraZeneca and insitro: reports give October 15 or October 16.
  • Takeda and Iambic: the upfront amount was not disclosed. The $1.7 billion figure is milestones only.

Methodology

Deals were included if they were announced in 2026, paired a drugmaker with a company that describes its platform as AI or computational, and had a company release or trade report we could open. Figures come from the linked source in each row. Where we could not open a company release, the row cites trade coverage, including Biotechgate and pharmaphorum roundups. Percentages are our own arithmetic. This page reports announced terms and is not investment advice. Status as of November 13, 2026.

Frequently Asked Questions

By headline value in this list, Eli Lilly and Insilico Medicine, announced March 29, 2026, at about $2.75 billion including milestones. The upfront payment was $115 million. SK Biopharmaceuticals and Insilico, announced June 22, is described as exceeding $2.5 billion with up to $18 million in upfront and near-term milestones.
AstraZeneca agreed to pay insitro $40 million upfront, with up to about $1.46 billion more in development and commercial milestones, according to trade reports of October 15 and 16, 2026. The collaboration covers MASH and cardiomyopathies.
No. Novo Nordisk and OpenAI (April 14, 2026), Bristol Myers Squibb and Anthropic (May 20, 2026) and Novo Nordisk and Anthropic (September 16, 2026) were all announced without financial terms.
Insilico said on July 2, 2026 that it will receive about $60 million in project initiation fees, near-term payments and milestones, and that the total could reach about $600 million with later milestones, plus tiered royalties. The release does not break out a separate upfront payment.
No. The two companies said on January 12, 2026 that they will jointly invest up to $1 billion over five years in talent, infrastructure and compute for a shared lab. They did not say how the amount is split.

Hire agents, not agencies.

Presenc is a team of AI agents that builds the pages your buyers search for, and a person checks every one. We take on a few teams at a time.

Request access